|
1
|
Agarwal S, Sane R, Ohlfest JR and Elmquist
WF: The role of the breast cancer resistance protein (ABCG2) in the
distribution of sorafenib to the brain. J Pharmacol Exp Ther.
336:223–233. 2011. View Article : Google Scholar :
|
|
2
|
Berasain C: Hepatocellular carcinoma and
sorafenib: too many resistance mechanisms? Gut. 62:1674–1675. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zhu Y, Zhu L, Lu L, Zhang L, Zhang G, Wang
Q and Yang P: Role and mechanism of the alkylglycerone phosphate
synthase in suppressing the invasion potential of human glioma and
hepatic carcinoma cells in vitro. Oncol Rep. 32:431–436.
2014.PubMed/NCBI
|
|
4
|
Lee C, Lee C, Lee S, Siu A and Ramos DM:
The cytoplasmic extension of the integrin β6 subunit regulates
epithelial-to-mesenchymal transition. Anticancer Res. 34:659–664.
2014.PubMed/NCBI
|
|
5
|
Ferlay J, Shin HR, Bray F, Forman D,
Mathers C and Parkin DM: Estimates of worldwide burden of cancer in
2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar
|
|
6
|
Gauthier A and Ho M: Role of sorafenib in
the treatment of advanced hepatocellular carcinoma: An update.
Hepatol Res. 43:147–154. 2013. View Article : Google Scholar :
|
|
7
|
Alam H, Kundu ST, Dalal SN and Vaidya MM:
Loss of keratins 8 and 18 leads to alterations in
α6β4-integrin-mediated signalling and decreased neoplastic
progression in an oral-tumour-derived cell line. J Cell Sci.
124:2096–2106. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ikushima H and Miyazono K: TGFbeta
signalling: a complex web in cancer progression. Nat Rev Cancer.
10:415–424. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Rigalli JP, Ciriaci N, Arias A, Ceballos
MP, Villanueva SS, Luquita MG, Mottino AD, Ghanem CI, Catania VA
and Ruiz ML: Regulation of multidrug resistance proteins by
genistein in a hepatocarcinoma cell line: impact on sorafenib
cytotoxicity. PLoS One. 3:e01195022015. View Article : Google Scholar
|
|
10
|
Kaposi-Novak P, Libbrecht L, Woo HG, Lee
YH, Sears NC, Coulouarn C, Conner EA, Factor VM, Roskams T and
Thorgeirsson SS: Central role of c-Myc during malignant conversion
in human hepatocarcinogenesis. Cancer Res. 69:2775–2782. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kim JK and Diehl JA: Nuclear cyclin D1: an
oncogenic driver in human cancer. J Cell Physiol. 220:292–296.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kollmann K, Heller G, Schneckenleithner C,
Warsch W, Scheicher R, Ott RG, Schäfer M, Fajmann S, Schlederer M,
Schiefer AI, Reichart U, et al: A kinase-independent function of
CDK6 links the cell cycle to tumor angiogenesis. Cancer Cell.
24:167–181. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lagas JS, van Waterschoot RA, Sparidans
RW, Wagenaar E, Beijnen JH and Schinkel AH: Breast cancer
resistance protein and P-glycoprotein limit sorafenib brain
accumulation. Mol Cancer Ther. 9:319–326. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Qiu JG, Zhang YJ, Li Y, Zhao JM, Zhang WJ,
Jiang QW, Mei XL, Xue YQ, Qin WM, Yang Y, Zheng DW, Chen Y, Wei MN
and Shi Z: Trametinib modulates cancer multidrug resistance by
targeting ABCB1 transporter. Oncotarget Apr. 14:2015.[Epub ahead of
print].
|
|
15
|
Lee YH, Judge AD, Seo D, Kitade M,
Gómez-Quiroz LE, Ishikawa T, Andersen JB, Kim BK, Marquardt JU,
Raggi C, Avital I, et al: Molecular targeting of CSN5 in human
hepatocellular carcinoma: a mechanism of therapeutic response.
Oncogene. 30:4175–4184. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Brózik A, Hegedüs C, Erdei Z, Hegedus T,
Özvegy-Laczka C, Szakács G and Sarkadi B: Tyrosine kinase
inhibitors as modulators of ATP binding cassette multidrug
transporters: substrates, chemo-sensitizers or inducers of acquired
multidrug resistance? Expert Opin Drug Metab Toxicol. 5:623–642.
2011. View Article : Google Scholar
|
|
17
|
Yagi K, Kawasaki Y, Nakamura H, Miura T,
Takeda T, Esumi S, Matsunaga H, Kitamura Y and Sendo T:
Differential combined effect of COX inhibitors on cell survival
suppressed by sorafenib in the HepG2 cell line. Biol Pharm Bull.
37:1234–1240. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sawyers CL: Shifting paradigms: the seeds
of oncogene addiction. Nat Med. 15:1158–1161. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Shackleford TJ and Claret FX: JAB1/CSN5: a
new player in cell cycle control and cancer. Cell Div. 18:262010.
View Article : Google Scholar
|
|
20
|
Shibayama Y, Nakano K, Maeda H, Taguchi M,
Ikeda R, Sugawara M, Iseki K, Takeda Y and Yamada K: Multidrug
resistance protein 2 implicates anticancer drug-resistance to
sorafenib. Biol Pharm Bull. 34:433–435. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Smalley KS, Xiao M, Villanueva J, Nguyen
TK, Flaherty KT, Letrero R, Van Belle P, Elder DE, Wang Y,
Nathanson KL and Herlyn M: CRAF inhibition induces apoptosis in
melanoma cells with non-V600E BRAF mutations. Oncogene. 28:85–94.
2009. View Article : Google Scholar
|
|
22
|
Thomas MB, O'Beirne JP, Furuse J, Chan AT,
Abou-Alfa G and Johnson P: Systemic therapy for hepatocellular
carcinoma: cytotoxic chemotherapy, targeted therapy and
immunotherapy. Ann Surg Oncol. 15:1008–1014. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wilhelm SM, Adnane L, Newell P, Villanueva
A, Llovet JM and Lynch M: Preclinical overview of sorafenib, a
multikinase inhibitor that targets both Raf and VEGF and PDGF
receptor tyrosine kinase signaling. Mol Cancer Ther. 7:3129–3140.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yip KW and Reed JC: Bcl-2 family proteins
and cancer. Oncogene. 50:6398–6406. 2008. View Article : Google Scholar
|
